Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience

Yong Joon Lee; Hyungdon Kook; Young Guk Ko; Cheol Woong Yu; Hyung Joon Joo; Chul Min Ahn; Donghoon Choi

doi:10.1016/j.ejvs.2020.10.008

Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience

Yong Joon Lee, Hyungdon Kook, Young Guk Ko, Cheol Woong Yu, Hyung Joon Joo, Chul Min Ahn, Donghoon Choi

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Objective: There have been limited clinical trials comparing drug eluting stents (DESs) and drug coated balloons (DCBs) in the treatment of femoropopliteal artery disease. This two centre retrospective and prospective cohort study sought to compare DES with DCB for the treatment of native femoropopliteal artery disease. Methods: A total of 288 limbs (242 patients) with native femoropopliteal artery disease were treated with DESs (Zilver PTX; 102 limbs) or DCBs (IN.PACT Admiral; 186 limbs) in two Korean endovascular centres between 19 January 2013 and 5 May 2018 and followed for a median duration of 19.6 months. The primary endpoint was primary clinical patency. Propensity score matching (PSM, 162 limbs) and inverse probability weighted (IPW) adjustment were performed to adjust for confounding baseline characteristics. Results: The DCB group had fewer lesions with Trans-Atlantic Inter-Society Consensus (TASC) II type C/D (55.9% vs. 70.6%, p =.021) or total occlusions (43.5% vs. 77.5%, p <.001) and showed shorter lesion lengths (164.2 ± 105.4 mm vs. 194.8 ± 86.8 mm, p =.009) than the DES group. After PSM, baseline clinical and lesion characteristics of the two groups were comparable except for larger reference vessel diameter in the DES group (5.4 ± 0.6 vs. 5.1 ± 0.7, p =.025). Adjunctive atherectomy was performed in 32.1% of the DCB group and in 2.5% of the DES group (p <.001). The provisional stenting was required in 14.8% of the DCB group. At two year follow up, the DCB group showed higher primary clinical patency (74.6% vs. 56.7%, hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.27–0.96, p =.032) and freedom from target lesion revascularisation (85.9% vs. 71.3%, HR 0.39, 95% CI 0.17–0.89, p =.021) than the DES group. Survival from all cause death did not differ between groups (87.6% vs. 92.1%, HR 1.85, 95% CI 0.62–5.52, p =.26). Conclusion: In this two centre cohort, DCBs with selective use of adjunctive atherectomy achieved more favourable outcomes than DESs for native femoropopliteal artery disease.

Original language	English
Pages (from-to)	287-295
Number of pages	9
Journal	European Journal of Vascular and Endovascular Surgery
Volume	61
Issue number	2
DOIs	https://doi.org/10.1016/j.ejvs.2020.10.008
Publication status	Published - 2021 Feb

Bibliographical note

Funding Information:
This study was supported by grants from the , Ministry of Health and Welfare , Republic of Korea (Nos. A085136 and HI15C1277 ), Mid-Career Researcher Program through the National Research Foundation , Ministry of Education, Science and Technology , Republic of Korea (No. 2015R1A2A2A01002731 ), and Cardiovascular Research Centre , Seoul, Korea.

Funding Information:
This study was supported by grants from the, Ministry of Health and Welfare, Republic of Korea (Nos. A085136 and HI15C1277), Mid-Career Researcher Program through the National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea (No. 2015R1A2A2A01002731), and Cardiovascular Research Centre, Seoul, Korea.

Publisher Copyright:
© 2020 European Society for Vascular Surgery

All Science Journal Classification (ASJC) codes

Surgery
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ejvs.2020.10.008

Cite this

@article{6544504142a74a5f9c194a68f7761499,

title = "Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience",

abstract = "Objective: There have been limited clinical trials comparing drug eluting stents (DESs) and drug coated balloons (DCBs) in the treatment of femoropopliteal artery disease. This two centre retrospective and prospective cohort study sought to compare DES with DCB for the treatment of native femoropopliteal artery disease. Methods: A total of 288 limbs (242 patients) with native femoropopliteal artery disease were treated with DESs (Zilver PTX; 102 limbs) or DCBs (IN.PACT Admiral; 186 limbs) in two Korean endovascular centres between 19 January 2013 and 5 May 2018 and followed for a median duration of 19.6 months. The primary endpoint was primary clinical patency. Propensity score matching (PSM, 162 limbs) and inverse probability weighted (IPW) adjustment were performed to adjust for confounding baseline characteristics. Results: The DCB group had fewer lesions with Trans-Atlantic Inter-Society Consensus (TASC) II type C/D (55.9% vs. 70.6%, p =.021) or total occlusions (43.5% vs. 77.5%, p <.001) and showed shorter lesion lengths (164.2 ± 105.4 mm vs. 194.8 ± 86.8 mm, p =.009) than the DES group. After PSM, baseline clinical and lesion characteristics of the two groups were comparable except for larger reference vessel diameter in the DES group (5.4 ± 0.6 vs. 5.1 ± 0.7, p =.025). Adjunctive atherectomy was performed in 32.1% of the DCB group and in 2.5% of the DES group (p <.001). The provisional stenting was required in 14.8% of the DCB group. At two year follow up, the DCB group showed higher primary clinical patency (74.6% vs. 56.7%, hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.27–0.96, p =.032) and freedom from target lesion revascularisation (85.9% vs. 71.3%, HR 0.39, 95% CI 0.17–0.89, p =.021) than the DES group. Survival from all cause death did not differ between groups (87.6% vs. 92.1%, HR 1.85, 95% CI 0.62–5.52, p =.26). Conclusion: In this two centre cohort, DCBs with selective use of adjunctive atherectomy achieved more favourable outcomes than DESs for native femoropopliteal artery disease.",

author = "Lee, {Yong Joon} and Hyungdon Kook and Ko, {Young Guk} and Yu, {Cheol Woong} and Joo, {Hyung Joon} and Ahn, {Chul Min} and Donghoon Choi",

note = "Funding Information: This study was supported by grants from the , Ministry of Health and Welfare , Republic of Korea (Nos. A085136 and HI15C1277 ), Mid-Career Researcher Program through the National Research Foundation , Ministry of Education, Science and Technology , Republic of Korea (No. 2015R1A2A2A01002731 ), and Cardiovascular Research Centre , Seoul, Korea. Funding Information: This study was supported by grants from the, Ministry of Health and Welfare, Republic of Korea (Nos. A085136 and HI15C1277), Mid-Career Researcher Program through the National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea (No. 2015R1A2A2A01002731), and Cardiovascular Research Centre, Seoul, Korea. Publisher Copyright: {\textcopyright} 2020 European Society for Vascular Surgery",

year = "2021",

month = feb,

doi = "10.1016/j.ejvs.2020.10.008",

language = "English",

volume = "61",

pages = "287--295",

journal = "European Journal of Vascular and Endovascular Surgery",

issn = "1078-5884",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease

T2 - A Two Centre Experience

AU - Lee, Yong Joon

AU - Kook, Hyungdon

AU - Ko, Young Guk

AU - Yu, Cheol Woong

AU - Joo, Hyung Joon

AU - Ahn, Chul Min

AU - Choi, Donghoon

N1 - Funding Information: This study was supported by grants from the , Ministry of Health and Welfare , Republic of Korea (Nos. A085136 and HI15C1277 ), Mid-Career Researcher Program through the National Research Foundation , Ministry of Education, Science and Technology , Republic of Korea (No. 2015R1A2A2A01002731 ), and Cardiovascular Research Centre , Seoul, Korea. Funding Information: This study was supported by grants from the, Ministry of Health and Welfare, Republic of Korea (Nos. A085136 and HI15C1277), Mid-Career Researcher Program through the National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea (No. 2015R1A2A2A01002731), and Cardiovascular Research Centre, Seoul, Korea. Publisher Copyright: © 2020 European Society for Vascular Surgery

PY - 2021/2

Y1 - 2021/2

N2 - Objective: There have been limited clinical trials comparing drug eluting stents (DESs) and drug coated balloons (DCBs) in the treatment of femoropopliteal artery disease. This two centre retrospective and prospective cohort study sought to compare DES with DCB for the treatment of native femoropopliteal artery disease. Methods: A total of 288 limbs (242 patients) with native femoropopliteal artery disease were treated with DESs (Zilver PTX; 102 limbs) or DCBs (IN.PACT Admiral; 186 limbs) in two Korean endovascular centres between 19 January 2013 and 5 May 2018 and followed for a median duration of 19.6 months. The primary endpoint was primary clinical patency. Propensity score matching (PSM, 162 limbs) and inverse probability weighted (IPW) adjustment were performed to adjust for confounding baseline characteristics. Results: The DCB group had fewer lesions with Trans-Atlantic Inter-Society Consensus (TASC) II type C/D (55.9% vs. 70.6%, p =.021) or total occlusions (43.5% vs. 77.5%, p <.001) and showed shorter lesion lengths (164.2 ± 105.4 mm vs. 194.8 ± 86.8 mm, p =.009) than the DES group. After PSM, baseline clinical and lesion characteristics of the two groups were comparable except for larger reference vessel diameter in the DES group (5.4 ± 0.6 vs. 5.1 ± 0.7, p =.025). Adjunctive atherectomy was performed in 32.1% of the DCB group and in 2.5% of the DES group (p <.001). The provisional stenting was required in 14.8% of the DCB group. At two year follow up, the DCB group showed higher primary clinical patency (74.6% vs. 56.7%, hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.27–0.96, p =.032) and freedom from target lesion revascularisation (85.9% vs. 71.3%, HR 0.39, 95% CI 0.17–0.89, p =.021) than the DES group. Survival from all cause death did not differ between groups (87.6% vs. 92.1%, HR 1.85, 95% CI 0.62–5.52, p =.26). Conclusion: In this two centre cohort, DCBs with selective use of adjunctive atherectomy achieved more favourable outcomes than DESs for native femoropopliteal artery disease.

AB - Objective: There have been limited clinical trials comparing drug eluting stents (DESs) and drug coated balloons (DCBs) in the treatment of femoropopliteal artery disease. This two centre retrospective and prospective cohort study sought to compare DES with DCB for the treatment of native femoropopliteal artery disease. Methods: A total of 288 limbs (242 patients) with native femoropopliteal artery disease were treated with DESs (Zilver PTX; 102 limbs) or DCBs (IN.PACT Admiral; 186 limbs) in two Korean endovascular centres between 19 January 2013 and 5 May 2018 and followed for a median duration of 19.6 months. The primary endpoint was primary clinical patency. Propensity score matching (PSM, 162 limbs) and inverse probability weighted (IPW) adjustment were performed to adjust for confounding baseline characteristics. Results: The DCB group had fewer lesions with Trans-Atlantic Inter-Society Consensus (TASC) II type C/D (55.9% vs. 70.6%, p =.021) or total occlusions (43.5% vs. 77.5%, p <.001) and showed shorter lesion lengths (164.2 ± 105.4 mm vs. 194.8 ± 86.8 mm, p =.009) than the DES group. After PSM, baseline clinical and lesion characteristics of the two groups were comparable except for larger reference vessel diameter in the DES group (5.4 ± 0.6 vs. 5.1 ± 0.7, p =.025). Adjunctive atherectomy was performed in 32.1% of the DCB group and in 2.5% of the DES group (p <.001). The provisional stenting was required in 14.8% of the DCB group. At two year follow up, the DCB group showed higher primary clinical patency (74.6% vs. 56.7%, hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.27–0.96, p =.032) and freedom from target lesion revascularisation (85.9% vs. 71.3%, HR 0.39, 95% CI 0.17–0.89, p =.021) than the DES group. Survival from all cause death did not differ between groups (87.6% vs. 92.1%, HR 1.85, 95% CI 0.62–5.52, p =.26). Conclusion: In this two centre cohort, DCBs with selective use of adjunctive atherectomy achieved more favourable outcomes than DESs for native femoropopliteal artery disease.

UR - http://www.scopus.com/inward/record.url?scp=85092523682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092523682&partnerID=8YFLogxK

U2 - 10.1016/j.ejvs.2020.10.008

DO - 10.1016/j.ejvs.2020.10.008

M3 - Article

C2 - 33223281

AN - SCOPUS:85092523682

SN - 1078-5884

VL - 61

SP - 287

EP - 295

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

IS - 2

ER -

Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this